Perspective Therapeutics (NYSE: CATX) files updated corporate presentation on 8-K

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. filed a current report to note that on September 2, 2025, the company updated its corporate presentation. The updated presentation is included as Exhibit 99.1 and is incorporated by reference into the disclosure. This type of presentation typically provides an overview of the business and strategy for investors, but the specific contents are not detailed here.

0000728387false00007283872025-09-022025-09-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2025

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CATX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 2, 2025, Perspective Therapeutics, Inc. updated its corporate presentation. A copy of the presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	September 2, 2025	By:	/s/ Juan Graham
			Juan Graham Chief Financial Officer

FAQ

What did Perspective Therapeutics (CATX) report in this 8-K filing?

Perspective Therapeutics reported that it updated its corporate presentation on September 2, 2025, and filed the updated presentation as Exhibit 99.1.

What is Exhibit 99.1 in Perspective Therapeutics' CATX 8-K?

Exhibit 99.1 is the updated corporate presentation of Perspective Therapeutics, Inc., which is incorporated by reference into the 8-K under Item 8.01.

Does this Perspective Therapeutics 8-K include new financial results?

No financial statements or earnings data are described in this excerpt. The 8-K focuses on the filing of an updated corporate presentation as an exhibit.

Why did Perspective Therapeutics file an 8-K for its corporate presentation?

The company used the 8-K to formally disclose that it updated its corporate presentation and to make that presentation publicly available as Exhibit 99.1.

Who signed the Perspective Therapeutics (CATX) 8-K?

The report was signed on behalf of Perspective Therapeutics, Inc. by Juan Graham, Chief Financial Officer, dated September 2, 2025.

What exchange is Perspective Therapeutics' common stock listed on?

The company’s common stock, par value $0.001, trades under the symbol CATX on the NYSE American LLC.